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Innate lymphoid cells (ILCs) producing IL-22 and/or IL-17, designated as ILC3, comprise
a heterogeneous subset of cells involved in regulation of gut barrier homeostasis and
inflammation. Exogenous environmental cues in conjunction with regulated expression
of endogenous factors are key determinants of plasticity of ILC3 toward the type 1 fate.
Herein, by usingmousemodels and transcriptomic approaches, we defined at themolecu-
lar level, initial events driving ILC3 expressing natural cytotoxicity receptors (NCR+ ILC3)
to acquire type 1 features. We observed that NCR+ ILC3 exhibited high basal expres-
sion of the signal-dependent transcription factor STAT4 due to T-BET, leading to predis-
posed potential for the type 1 response. We found that the prototypical inducer of type 3
response, IL-23, played a predominant role over IL-12 by accessing STAT4 and preferen-
tially inducing its phosphorylation in ILC3 expressing T-BET. The early effector program
driven by IL-23 was characterized by the expression of IL-22, followed by a production
of IFN-γ, which relies on STAT4, T-BET and required chromatin remodeling of the Ifng
locus. Altogether, our findings shed light on a feed-forward mechanism involving STAT4
and T-BET that modulates the outcome of IL-23 signaling in ILC3.
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Introduction
Lymphocyte specification is controlled by regulated expression
of lineage-defining (LDTF) and signal-dependent transcription
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factors (SDTF). Based on the expression pattern of LDTFs and
cytokines, three major groups of innate lymphoid cells can be
discriminated [1]. Mirroring the typical traits of distinct T cell
subsets, type 1 ILCs comprise natural killer (NK) cells and other
interferon-γ (IFN-γ)-producing cells, overall named ILC1, whereas
innate lymphocytes producing cytokines associated with T helper
2 response fall into the ILC2 group. Finally, type 3 ILCs (ILC3) are
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generally characterized by the expression of interleukin (IL)-22
and requirement of the LDTF RORγt [2]. Distinct ILC3 subsets can
be further discerned based on the expression of CD4, CCR6 and
natural cytotoxicity receptors (NCRs) [3, 4]. Despite their pheno-
typic similarity with NK cells, NCR+ ILC3 were initially identified
for their ability to produce IL-22, both in human and mouse, and
lack of the typical NK cell effector functions [5–8]. However, the
requirement of the LDTFs of ILC1, T-BET (encoded by Tbx21),
functionally positions these cells as a bridge between type 1 and
type 3 ILCs [9–11], and delineates their hybrid transcriptional and
epigenetic programs [12, 13].
NCR+ ILC3 are predominantly located in the lamina propria
of the intestine, having both redundant and nonredundant roles
in promoting gut inflammation [14, 15]. In this context, SDTFs
can shape the effector programs of NCR+ ILC3. Among them,
members of the Signal Transducer and Activator of Transcription
(STAT) family play a pivotal role in regulation of ILC functions
[16]. Beyond STAT5, which orchestrates the development of all
ILCs and has a peculiar requirement in NCR+ ILC3 [17], STAT3 has
been demonstrated to be a key regulator of the effector functions
of the whole ILC3 compartment, downstream of IL-23 activity
[18, 19]. On the other hand, STAT4 has specific roles in regulating
NK cells and ILC1 functions; however, the controlled expression of
STAT4 is important for determining NK functional output during
course of infection [20–22].
IL-12 and IL-23, two cytokines that signal via STAT4, have
been implicated in the functional plasticity of NCR+ ILC3 toward
the ILC1 phenotype [10, 23–25]; however, the mechanistic basis
of this phenomenon have not yet been characterized. In this
study, through the combination of mouse models and genomic
approaches, we assessed the expression of STAT4 in ILC3, the
role of T-BET in regulation of its expression and its functional
relevance. We observed that expression of T-BET, along with the
selective ability of IL-23 to induce both STAT4 activation and epi-
genetic changes led to distinct effector programs in ILC3. Thus, dif-
ferent ILC3 subsets can have distinct activation outcomes through
the coordinated expression of both LDTFs, and regulated expres-
sion of SDTFs.
Results and discussion
NCR+ ILC3 selectively express high basal levels of
STAT4
We began our investigations by examining STAT4 expression in
ILC3 subsets under basal conditions. We analyzed CD3ε−RORγt+
cells based on the expression of NKp46 and CD4, and included
RORγt−NKp46+ cells, which comprise both ILC1 and NK cells, as
controls (Fig. 1A and Supporting Information Fig. 1A). As shown
in Fig. 1B, type 1 ILCs expressed high levels of STAT4, reflecting its
previously established role in regulating NK and ILC1 functions.
However, STAT4 expression was not restricted to type 1 cells,
since we also found high basal levels of this TF in NCR+ ILC3. In
contrast, STAT4 was barely detectable in CD4+ ILC3 (Fig. 1B).
NCR+ ILC3 originate from a fraction of CD4−NCR− ILC3 that
express T-BET [11]. Thus, we further analyzed the latter ILC3
population for T-BET expression and STAT4 levels. Notably, we
mainly detected STAT4 expression in the fraction of T-BET+ cells
(Fig. 1C), although at lower levels as compared to NCR+ ILC3
(Fig. 1D). These data indicated that both the LDTF and SDTF
leading the type 1 effector programs emerge simultaneously in
ILC3. This observation led us to investigate whether T-BET could
have a role in regulation of STAT4 expression.
T-BET+ ILC3 are characterized by the low expression of the
chemokine receptor CCR6. The absence of T-BET in CCR6− ILC3
results in a developmental block, and accumulation of cells in
the intestinal lamina propria that lack expression of NCR recep-
tors [10]. As shown in Fig. 1E, CCR6− ILC3 isolated from Tbx21−/−
mice lack the high STAT4 expression that is seen in their WT
counterparts, indicating T- BET as an inducer of STAT4 expression
in this subset of ILCs. The differential STAT4 expression observed
in ILC3 was correlated with the presence of regulatory elements
specifically accessible in the Stat4 locus of NCR+ ILC3 (Support-
ing Information Fig. 1B). In support of the direct role of T-BET
underlying STAT4 expression, these specific regulatory elements
corresponded to T-BET-binding sites (Supporting Information
Fig. 1B).
In contrast to ILC3, there was only a trend showing a partial
reduction of STAT4 expression in Tbx21−/− type 1 ILCs (Support-
ing Information Fig. 1C), arguing for alternative means of regu-
lation in these cells. In this regard, the expression of the other
T-BOX family member, EOMES, observed in the NK cells persist-
ing in Tbx21−/− mice could compensate for the absence of T-BET
[9].
Thus, our data show selective high basal STAT4 expression
levels in NCR+ ILC3, equivalent to that of ILC1, correlating with
T-BET expression. Moreover, our findings provide evidence for the
requirement of T-BET for maintenance of STAT4 in ILC3 but not
ILC1.
IL-23 drives STAT4 activation in NCR+ ILC3
IL-23 and IL-12 are most often linked to STAT3 and STAT4 acti-
vation, respectively. Many, if not all, cytokines activate multi-
ple STATs and the output of cytokine signaling is modulated by
the dynamic regulated expression of different STATs [20, 26].
Moreover, as IL-23 and IL-12 share a receptor subunit, they
both have the capacity to induce robust STAT4 phosphorylation
[27].
Therefore, we measured the activity of both cytokines in NCR+
ILC3 and type 1 ILCs, positing that with high basal STAT expres-
sion, the typical preferential STAT usage might be altered. As
shown in Fig. 2A, IL-23 induced STAT4 phosphorylation in NCR+
ILC3, along with prominent STAT3 phosphorylation, in contrast
to ILC1 in which neither STAT was activated (see also Support-
ing Information Fig. 2A). By contrast, IL-12 activated STAT4, and
partially STAT3, only in type 1 ILCs (Fig. 2B and Supporting Infor-
mation 2B).
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Figure 1. STAT4 is differentially expressed in ILC3. (A) STAT4 expression was analyzed in ILCs discriminated based on RORγt, NKp46 and CD4
expression. Type 1 ILCs are defined as CD3ε−RORγt−NKp46+ cells; CD3ε−RORγt+ ILC3 are divided in three populations according to CD4 and NKp46.
(B) Histogram overlay shows basal STAT4 expression levels in the indicated ILC subsets. (C) Density plot depicts STAT4 expression relative to T-BET
in NCR−CD4− ILC3. (D) Box plot depicts STAT4 expression in the different ILC subsets; measured as median of the percentage of positive cells,
relative to control. (E) STAT4 expression in ILC3 isolated from WT and Tbx21−/− mice; ILC3 populations are defined according to CCR6 expression
(left panel); histogram overlay shows basal STAT4 expression levels in the indicated ILC subsets (right panel). Fig. 1, A-C is representative of 5
independent experiments with 1 mouse per experiment and (D) shows pooled data. Fig. 1E is pooled from 3 independent experiments with 1–2
mouse/group per experiment.
Divergent and redundant transcriptomic
effects of IL-23 in ILC3
To define the potential impact of IL-23 stimulation in cells that
manifest differential STAT3 and STAT4 activation, we analyzed
the transcriptomes of NCR+ and CD4−NCR− ILC3 acutely treated
with this cytokine (Supporting Information Table 1). In effort to
gain further functional insights, we used a stringent cut-off [28]
(fold change higher than 4) to identify the most highly IL-23
regulated genes in each population (Supporting Information
Table 2, for complete list of upregulated and downregulated
genes). Through this approach, we defined 51 highly induced
genes in NCR+ and 38 in CD4−NCR− ILC3. Transcripts encoding
for genes typically associated with the type 3 response, such as
Il22, Il1r1, Socs3 and Il17f were at the top of the two gene lists
(Fig. 2C). By analysis of the absolute expression, we identified
both specific (cluster 1 and 3) and redundant (cluster 2) acti-
vation programs downstream of IL-23 between 2 populations
Figure 2. Transcriptomic changes
induced by IL-23 in NCR+ ILC3. (A, B)
STAT4 and STAT3 phosphorylation
following IL-23 and IL-12 stimulation
was performed in NCR+ ILC3 and type 1
ILCs. A representative experiment of 4
experiments with 1 mouse per experi-
ment is shown. (C) Volcano plot depicts
the transcripts upregulated (red) and
downregulated (blue) by IL-23 in NCR+
and CD4−NCR− ILC3 (4-h treatment; FC
> 4), see also Supporting Information
Table 2. (D) Expression of highly induced
transcripts (FC >4) established in (C) is
depicted by heatmap, comparing IL-23
stimulated NCR+ ILC3 and CD4−NCR−
ILC3. Three main subsets are defined
based on hierarchical clustering. RNA-
seq in Fig. 2C and D was performed in
duplicates per condition (25 mice were
pooled for each duplicate). (E) Quadrant
from flow cytometry plot shows IL-22
and IFN-γ expression in NCR+ ILC3. A
representative experiment of three with
one mouse per experiment is shown.
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Figure 3. IL-23 drives IFN-γ expression in
NCR+ ILC3. (A) Flow cytometry quadrant
plots show CD3ε− RORγt+ ILC3, dissected
based on NKp46 and CD4 expression.
Numbers indicate the frequency (mean
± SD) of NCR+ cells, in WT (n = 7) and
STAT4−/− (n = 5) mice, among ILC3. A rep-
resentative of 3 independent experiments
performed is shown. (B) Bar graph depicts
percentage (mean + SD) of IL-22+ NCR+
ILC3 after IL-23 stimulation (4 h) in WT
(black) and STAT4−/− (white) mice, (data
pooled from 3 independent experiments
with 1 mouse/group per experiment). (C)
Genome track view of the Ifng locus show-
ing ATAC-seq for ex vivo isolated NK cells,
unstimulated and stimulated NCR+ ILC3.
(D) Bar graph depicts percentage (mean
+ SD) of IFN-γ+ NCR+ ILC3 after IL-23
stimulation, at different time points (4,
8, 16h); (3 independent experiments were
performed with 1 mouse/group per exper-
iment). (E) Quadrants in flow cytometry
plots depict IFN-γ production in NCR+
ILC3, CD4−NCR−ILC3 and type 1 ILCs after
IL-23 stimulation (16 h) a representative
experiment of 3 experiments performed
with 1 mouse per experiment is shown.
(F) Bar graphs depict percentage (mean +
SD) of IFN-γ+ NCR+ ILC3 and IFN-γ+ NCR−
ILC3 after IL-23 stimulation (16 h), in WT
(n = 3) and STAT4−/− mice (n = 4) from 2
independent experiments. (G) Quadrants
in flow cytometry plots depict expression
of IL-22 and IFN-γ in NCR+ and CD4−NCR−
ILC3 after IL-23 stimulation (4 h) in mice
(DSS-colitis, day 7). Histogram plots depict
percentage (mean + SD) of IFN-γ+ in NCR+
and CD4−NCR− ILC3 (n = 3, in 2 inde-
pendent experiments performed). Where
indicated asterisks denote significant dif-
ferences (P < 0.05); N.S., not significant.
of ILC3 (Fig. 2D, and Supporting Information Table 3). Genes
encoding IL-17 were highly expressed mainly in NCR− ILC3 (as
previously described [29, 30]), whereas Il22, Il1r1 and Socs3
were expressed at similar levels in both ILC3 populations, after
IL-23 stimulation. Finally, in activated NCR+ ILC3, we observed
prominent expression of transcripts previously associated with
the NK cell response, such as Ccr5, Gzma, Prdm1 (encoding for
BLIMP1) and Ifitm1 [31]. In contrast to the high expression levels
of IL-22, and the induction of NK cell related genes, the epony-
mous cytokine of the type 1 response, IFN-γ, was not induced
either at RNA (Fig. 2C,D) or protein level (Fig. 2E) after this
acute stimulation of 4 h, which led us to further investigate the
mechanisms underlying differential regulation of IL-22 and IFN-γ.
Asymmetric regulation of IL-22 and IFN-γ in
NCR+ ILC3
Despite of the pivotal role of T-BET and the activity of IL-23 in reg-
ulation of the homeostatic pool of NCR+ ILC3 [9–11], the deletion
of Stat4 did not affect generation of this subset. Indeed, Stat4−/−
mice did not present significant alterations of the ILC3 popula-
tions (Fig. 3A). Thus, we capitalized on the preservation of NCR+
ILC3 in Stat4−/− mice to evaluate the functional role of this TF in
regulating IL-22 and IFN-γ expression. After treatment with IL-23,
both WT and Stat4−/− NCR+ ILC3 expressed comparable levels
of IL-22 (Fig. 3B), as well, expression of the two LDTFs, T-BET
and RORγt was not altered in Stat4−/− mice (Supporting Infor-
mation Fig. 3A). On the other hand, as shown in Fig. 2E, IFN-γ
production was not detected at the time when IL-22 was produced
in WT cells despite that IL-23 activated both STAT3 and STAT4
(Fig. 2A). To gain further insight into the regulation of IFN-γ,
we evaluated chromatin accessibility of the Ifng locus, including
distal enhancer elements. While resting NCR+ ILC3 showed lim-
ited accessibilities of the Ifng locus compared with NK cells, we
observed de novo appearance of accessible regulatory elements
induced by IL-23 treatment (Fig. 3C). This led us to hypothesize
that delayed expression of IFN-γ could be occurring. In support of
this hypothesis, we observed production of IFN-γ in NCR+ ILC3
after 8- and 16-hour stimulation with IL-23 (Fig. 3D). In these
conditions, NCR+ ILC3 were the main producer of IFN-γ, not
only in the context of ILCs (Fig. 3E and Supporting Information
Fig. 3B), but also when compared to total CD3ε+ T cells (Support-
ing Information Fig. 3C). Notably, Stat4 deletion was associated
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with a reduced IFN-γ response in NCR+ ILC3 after IL-23 treat-
ment, while no significant difference was observed in CD4−NCR−
ILC3 (Fig. 3F). Our observation collectively predicts that NCR+
ILC3 holds the potential to become not only IL-22 but also IFN-
γ producers in response to inflammatory environment and their
IFN-γ response is partially through STAT4.
To address the in vivo relevance of our findings, we tested
a colitis model and evaluated the expression of IFN-γ in ILC3.
In these settings, NCR+ ILC3 still maintained their preferential
responsivity to IL-23, over IL-12 (data not shown), and were able
to respond as IFN-γ producers when challenged with IL-23 in vitro
both at long time points (8 h, data not shown), and after a short
exposure (4 h, Fig. 3G). Together, our data provide a mechanism
for differential function in ILC3 subsets. Whereas IL-22 expres-
sion is independent of STAT4 and occurs early during activation,
IFN-γ expression in NCR+ ILC3 is slightly delayed and requires
T-BET, STAT4, and associated chromatin changes of regulatory
elements.
Concluding remarks
Our study sheds light on a mechanism by which a lymphocyte
subset can perceive a single cytokine very differently based on
the regulated expression of an LDTF and SDTF (model in Sup-
porting Information Fig. 4). The mechanism allows for functional
plasticity in ILC3, without a global phenotypic transition to a dif-
ferent state, i.e. type 1 ILCs. This property relies on the presence
of the LDTF T-BET, which represents the first condition predis-
posing a subset of ILC3 toward a type 1 response. Subsequently,
the type 1 response is amplified by high basal levels of STAT4
induced by T-BET. The coordinated expression of T-BET together
with high STAT4 levels allows IL-23 to induce genes associated
with both a type 1 response and type 3 response. Most notably,
IL-23-induced robust STAT4 phosphorylation leads to an efficient
IFN-γ production in NCR+ ILC3. Our results provide a translational
rationale why targeting IL-23 alone could have therapeutic poten-
tial for inflammatory bowel disease and colon cancer in which
the ILC3/IL-23 axis was reported to play a major role [19, 32].
Similarly, IL-23 targeting therapy would be beneficial in Crohn’s
disease in which the accumulation of IFN-γ producing ILCs was
reported [33]. Most importantly, our findings help explain why
targeting IL-23 and IL- 17 are not synonymous and have divergent
consequences in clinical trials; anti-IL-23 therapies (ustekinumab,
guselkumab, tildrakizumab) provided benefit whereas anti-IL-17
therapy (secukinumab) exacerbated inflammation [34].
Materials and methods
Mice
Female C57BL/6J and Tbx21−/− mice were purchased from Jack-
son Laboratory; STAT4−/− mice were provided by M Kaplan [35].
All animal studies were performed according to the NIH guide-
lines for the use and care of live animals and were approved by
the Institutional Animal Care and Use Committee of NIAMS and
Italian Ministry of Health.
Cell isolation and activation
Cells from the small intestinal lamina propria (siLP) were isolated
after incubation of intestine in RPMI with 0.5 mg/mL DNase I
and 0.25 mg/mL Liberase TL (Roche), and purification with 40%
Percoll [9]. Cells were stimulated in RPMI medium with 10%
FCS, 2 mM glutamine, 100 IU/mL penicillin, 0.1 mg/mL strepto-
mycin, 20 mMHEPES buffer (pH 7.2–7.5) (Invitrogen); and 2 mM
β-mercaptoethanol (Sigma-Aldrich). Cells were left untreated or
stimulated with IL-23 (50–100 ng/mL; R&D Systems) for 30 min-
utes for evaluation of phosphorylated-STATs; for 4, 8 or 16 h
(addition of brefeldin A; GolgiPlug; BD, for 4 h) for evaluation
of cytokine expression. In the colitis model, siLP cells were iso-
lated from mice treated with 3% DSS (MW 36–50kD, 160110, MP
Biomedicals) in the drinking water. Weight loss was monitored,
and mice were sacrificed at day 7.
Flow cytometry
Cell surface staining was performed with anti-mouse CCR6
(140706), CD3ε (145- 2C11), CD4 (RM4-5), CD16/CD32 (2.4G2),
NK1.1 (PK136), NKp46 (29A1.4).
Cytofix/Cytoperm Fixation and Permeabilization solution (BD)
was used for anti-mouse IFN-γ (XMG1.2), IL-22 (1H8PWSR),
RORγt (B2D), and T-BET (eBio4B10) staining. Anti-STAT4 (8),
phosphorylated-STAT3 (4/P-STAT3) and phosphorylated-STAT4
(38/p-Stat4) were stained as described [20]. Antibodies were pur-
chased from eBioscience, BioLegend or BD. Samples were acquired
using FACSVerse or FACSCanto (BD Biosciences) and analyzed
with FlowJo software (Tree Star).
RNA sequencing and transcriptomic
analysis
Cells were treated with IL-23 (50 ng/mL) or left untreated, for
4h, after sorting using FACSAria III (BD). Cells isolated from
siLP were gated on Propidium Iodide (PI)−CD3ε−CD19−NKp46+
CD127+NK1.1− for NCR+ILC3; and PI−CD3ε−CD19−NKp46−
CD127+KLRG1−CD4− for CD4−NCR− ILC3. Purity of sorted cells
ranges from 95 to 99% post sort. RNA-seq was performed as
described previously [36]. Briefly, total RNA was prepared from
50 000 cells by using TRIzol (Life Technologies), and processed
to generate mRNA-seq libraries using TruSeq SR mRNA sample
prep kit (FC-122-1001; Illumina). Libraries were sequenced for
50 cycles (single read) with a HiSeq 2000 or HiSeq 2500 (Illu-
mina). 50-bp reads were mapped onto mouse genome build mm9
using TopHat 2.1.0. Gene expression values (FPKM, fragments
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per kilobase exon per million mapped reads) were calculated with
Cufflinks 2.2.1 [37]. Statistical analysis of differentially expressed
genes (DEG) were performed with Partek Genomics Suite 6.6.
DEG were selected with following criteria: absolute FPKM>10 in
at least 1 condition; fold change >4; protein-coding-genes [38]
were included in this analysis. Estimated T cell contamination
was negligible based on the absence of Cd5 expression in the
dataset. Volcano plot was generated using R 3.0.1 (R Core Team,
2014); heatmap and hierarchical clustering using Morpheus soft-
ware (Broad Institute); genomic snapshots were generated using
IGV software (Broad Institute). Supporting Information Table 1
contains FPKM values for expressed genes (FPKM>10).
Statistics
Unpaired homoscedastic Student’s t test was used to quantify sta-
tistical deviation between experimental groups. Asterisks denote
significant differences (p < 0.05).
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